


Lecture 4 – Quantitative Evaluation of Binding Interactions




February 27, 2024

Molecular recognition is ubiquitous in biology



proteins, lipids, sugars, nucleic acids, metabolites, antibodies

The Inner Life of the Cell – Drs. Viel and Lue, Harvard



<https://www.youtube.com/watch?v=FzcTgrxMzZk>

8 minute video – watch it while you are running an experiment

Basic language of binding interactions

from 20.110

Affinity: strength of the interaction, measured by the corresponding decrease in free energy upon binding


Specificity: relative strength of interaction for a 'cognate' and 'non-cognate' receptor-ligand complex

Basic language of binding interactions

from 20.110

Affinity: strength of the interaction, measured by the corresponding decrease in free energy upon binding


Specificity: relative strength of interaction for a 'cognate' and 'non-cognate' receptor-ligand complex



Folate binding to Folate Receptor

There are two basic types of non-covalent interactions: simple binding and allosteric


Some binding interactions are '*simple*' equilibria – each encounter is independent



There are two basic types of non-covalent interactions: simple binding and allosteric


Some binding interactions are 'simple' equilibria – each encounter is independent

simple interaction



Others are more complex, involving *allostery*, where one ligand binding event alters the affinity for another ligand

allosteric interaction




Thermodynamic analyses provide insight into molecular interactions

As you learned in 20.110, we can think about the following binding-related terms thermodynamically:

- affinity and specificity
- contribution of entropy and enthalpy
- dependence on temperature
- contributions of chemical groups on the ligand and/or the receptor

This information can in turn be used to understand a system and to alter the system (e.g. drug design)

Relationship of ligand binding free energy to association constants



From 20.110:

$$\Delta G_{\text{bind}}^{\circ} = -RT \ln K_A$$




$$K_D = \frac{[P][L]}{[P \cdot L]} = \frac{1}{K_A}$$

(dissociation constant)

$$\Delta G_{\text{bind}}^{\circ} = + RT \ln K_D$$

Binding isotherms are half maximal at
 $[L] = K_D$


'binding isotherm plot'



intermediate ligand concentration: $f = 0.5$
 $K_D = [L]$ when $f = 0.5$

steady-state
equilibrium analysis

Logarithmic vs. Linear display of data



as a corollary, choose your concentrations wisely:

1, 3, 10, 30, 100, 300 nM

vs.

50, 100, 150, 200, 250, 300 nM

A range of affinities enable biology


Type of Interaction	K_D (molar)	ΔG_{bind}^0 (at 300K) kcal/mol
Enzyme:ATP	$\sim 1 \times 10^{-3}$ to $\sim 1 \times 10^{-6}$ (millimolar to micromolar)	-4 to -8 kcal/mol
signaling protein binding to a target	$\sim 1 \times 10^{-6}$ (micromolar)	-8 kcal/mol
Sequence-specific recognition of DNA by a transcription factor	$\sim 1 \times 10^{-9}$ (nanomolar)	-12 kcal/mol
small molecule inhibitors of proteins (drugs)	$\sim 1 \times 10^{-9}$ to $\sim 1 \times 10^{-12}$ (nanomolar to picomolar)	-12 to -17 kcal/mol
biotin binding to avidin protein (strongest known non-covalent interaction)	$\sim 1 \times 10^{-15}$ (femtomolar)	-21 kcal/mol

higher K_D value
weaker interaction

lower K_D value
stronger interaction

Specificity in molecular recognition

discrimination among targets




Proteinase K

low specificity

Aliphatic/X
Aromatic/X

Lab Use - DNA/RNA preps




HRV 3C Protease

high specificity


Leu-Glu-Val-Leu-Phe-Gln/Gly-Pro

Lab Use – cleaving fusion proteins

Specificity in molecular recognition – kinase drugs



AC220




CEP-701




MLN-518

binding constants



PKC-412



CGP-52421




Sorafenib



Sunitinib


Specificity in drug binding – fractional saturation

deliver the drug at a concentration below the K_D for non-cognate target




Specificity in drug binding – fractional saturation

deliver the drug at a concentration below the TD_{50} in patients



impact therapeutic effects?

'Therapeutic Window'




ED_{50} = effective in 50% patients


TD_{50} = toxic in 50% patients

But how do we go about measuring these K_D values in a laboratory setting?


Methods to find or evaluate binding interactions




Methods to find or evaluate binding interactions



Measuring a thermal melt profile for a protein




Dyes used to detect protein unfolding




ANS

8-anilino-1-naphthalene-sulfonic acid
(1965)




Nile Red

9-diethylamino-5-benzo[a]phenoxazinone
(1985)



solvatochromic


Nile Red under visible and UV light in different solvents



SYPRO® Orange

Most common dye for DSF/TS
(2004)

binds nonspecifically to hydrophobic surfaces;
water quenches fluorescence




CPM


N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide
(2008)

only fluoresces after reacting with Cys residues


What happens when you add a small molecule?



Thermal shift assays with small molecules




Real thermal shift screens with small molecules



preferential ligand binding to unfolded states?


Real thermal shift screens with small molecules



preferential ligand binding to unfolded states?

Real results from thermal shift studies


assay development




consider optimizing buffer conditions – pH, cofactors

Real results with thermal shift assays

three replicates for a single experiment




raw fluorescence thermal curves




first derivative representation

Real results with thermal shift assays





raw fluorescence thermal
curves

Protein disorder continuum



Protein disorder continuum




MAX



Determining apparent dissociation constants

hexokinase (receptor) and glucose (ligand)




Experiment 1:

test a wide range of glucose concentrations

K_D is likely between 0.2 and 1.7 mM

Determining apparent dissociation constants


hexokinase (receptor) and glucose (ligand)



Experiment 1:

test a wide range of glucose concentrations

K_D is likely between 0.2 and 1.7 mM









Experiment 2:

test 16 concentration of glucose
fit to single binding event model (red)

apparent $K_D \sim 1.12 \pm 0.05$ mM

Target engagement in cells: **cellular thermal shift assays (CETSA)**TM monitor levels of soluble proteins



compound treatment
in live cells

heating and cooling


lyse cells

separation of
aggregates (optional)


detection

Anticipated results from CETSA assays

T_{agg} curve



ITDRF curves



IsoThermal Dose Response Fingerprint
'apparent potencies' at single temp


MIT News

ON CAMPUS AND AROUND THE WORLD

Browse

or

Search



Alveolar rhabdomyosarcoma, a soft tissue cancer


Image: Michael Bonert/Wikimedia Commons

Taking a moonshot at a rare childhood cancer


Team of researchers including MIT Professor Angela Koehler obtains \$5.8 million grant to study fusion-positive alveolar rhabdomyosarcoma.

PAX3-FOXO1

pathognomic fusion in alveolar rhabdomyosarcoma



PONDR®
Predictor of Natural
Disordered Regions




PAX3-FOXO1

pathognomic fusion in alveolar rhabdomyosarcoma


Preliminary SMM screening data for PAX3-FOXO1 from
HEK293T cell lysates

PAX3-FOXO1, FOXO1
CETSA


Pilot: ~10,000 small molecules




Temperature [°C]




CETSA for MAX Binder KI-MS2-008




dose-dependent
cellular thermal shift assays (CETSA)
in live cells



CETSA for MAX Binder KI-MS2-008



dose-dependent
cellular thermal shift assays (CETSA)
in live cells



Upcoming Lectures

2/8/24	Lecture 1	Intro to chemical biology: small molecules, probes, and screens
2/13/24	No Lecture	Snow Day
2/15/24	Lecture 2	Small Molecule Microarrays
2/20/24	No Lecture	
2/22/24	Lecture 3	Our protein target – MAX
2/27/24	Lecture 4	Quantitative evaluation of protein-ligand interactions
2/29/24	Lecture 5	KB-0742: A Phase 2 clinical candidate discovered by SMMs
3/5/23	Lecture 6	Wrap up discussion for Mod 1 experiments and report